5A/6A polymorphism of the stromelysin-1 gene and angiographic restenosis after coronary artery stenting

Kuan Rau Chiou, Sheng Liang Chung, Min Ji Charng

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Coronary stent deployment is a major advance in interventional treatment, but 20-40% of patients still develop in-stent restenosis (ISR) due to neointimal hyperplasia. Genetic factors play a role in restenosis. This study investigated the frequency of 5A/6A polymorphism in the promoter of the stromelysin-1 gene, and the issue of whether it contributes to restenosis among patients receiving coronary stent in the Chinese population in Taiwan. Methods: We investigated 344 symptomatic patients after successful coronary stent placement. All patients received repeated angiography after 6 months, or earlier if clinically indicated. Angiographic restenosis was defined as ≥ 50% diameter stenosis at follow-up. Genotyping for stromelysin-1 promoter was based on a polymerase chain reaction technique. Results: The stromelysin-1 gene promoter genotypes 5A5A, 5A6A, and 6A6A were distributed in 3.5%, 22.7%, and 73.8% of patients, respectively. The frequency of the 6A allele was 0.85. There was no significant difference in angiographic ISR between the non-6A6A and 6A6A groups (28.9% and 37.0%, respectively, p = 0.165). However, subgroup analysis revealed a significant difference in patients according to angina status. Among the 5A5A and 5A6A genotype groups, patients with unstable angina had significantly higher ISR rates than those with stable angina (48% vs 21.5%, p = 0.013). On the other hand, among patients with stable angina, those with a 6A6A genotype had a higher ISR rate than those with a non-6A6A genotype (p = 0.029), making the 6A6A genotype an independent predictor of ISR (odds ratio, 2.57; 95% confidence interval, 1.22-5.41; p = 0.013). Conclusion: There is a low frequency of the stromelysin-1 promoter 5A allele in the Chinese population in Taiwan. How stromelysin-1 5A/6A polymorphism affects ISR appears to be linked to angina status. These results merit further study to identify patients carrying genotypes which put them at increased risk of ISR, and which matrix metalloproteinase inhibitors or drug-eluting stents are more effective for those at risk.

Original languageEnglish
Pages (from-to)506-512
Number of pages7
JournalJournal of the Chinese Medical Association
Volume68
Issue number11
DOIs
Publication statusPublished - Jan 1 2005
Externally publishedYes

Fingerprint

Matrix Metalloproteinase 3
Stents
Coronary Vessels
Genes
Genotype
Stable Angina
Taiwan
Drug-Eluting Stents
Matrix Metalloproteinase Inhibitors
Unstable Angina
Gene Frequency
Population
Hyperplasia
Angiography
Pathologic Constriction
Alleles
Odds Ratio
Confidence Intervals

Keywords

  • Angioplasty
  • Genetics
  • Restenosis
  • Stet
  • Stromelysin-1

ASJC Scopus subject areas

  • Medicine(all)

Cite this

5A/6A polymorphism of the stromelysin-1 gene and angiographic restenosis after coronary artery stenting. / Chiou, Kuan Rau; Chung, Sheng Liang; Charng, Min Ji.

In: Journal of the Chinese Medical Association, Vol. 68, No. 11, 01.01.2005, p. 506-512.

Research output: Contribution to journalArticle

@article{90d1d4363fcd4a8d9e64bf7a2eda6d0f,
title = "5A/6A polymorphism of the stromelysin-1 gene and angiographic restenosis after coronary artery stenting",
abstract = "Background: Coronary stent deployment is a major advance in interventional treatment, but 20-40{\%} of patients still develop in-stent restenosis (ISR) due to neointimal hyperplasia. Genetic factors play a role in restenosis. This study investigated the frequency of 5A/6A polymorphism in the promoter of the stromelysin-1 gene, and the issue of whether it contributes to restenosis among patients receiving coronary stent in the Chinese population in Taiwan. Methods: We investigated 344 symptomatic patients after successful coronary stent placement. All patients received repeated angiography after 6 months, or earlier if clinically indicated. Angiographic restenosis was defined as ≥ 50{\%} diameter stenosis at follow-up. Genotyping for stromelysin-1 promoter was based on a polymerase chain reaction technique. Results: The stromelysin-1 gene promoter genotypes 5A5A, 5A6A, and 6A6A were distributed in 3.5{\%}, 22.7{\%}, and 73.8{\%} of patients, respectively. The frequency of the 6A allele was 0.85. There was no significant difference in angiographic ISR between the non-6A6A and 6A6A groups (28.9{\%} and 37.0{\%}, respectively, p = 0.165). However, subgroup analysis revealed a significant difference in patients according to angina status. Among the 5A5A and 5A6A genotype groups, patients with unstable angina had significantly higher ISR rates than those with stable angina (48{\%} vs 21.5{\%}, p = 0.013). On the other hand, among patients with stable angina, those with a 6A6A genotype had a higher ISR rate than those with a non-6A6A genotype (p = 0.029), making the 6A6A genotype an independent predictor of ISR (odds ratio, 2.57; 95{\%} confidence interval, 1.22-5.41; p = 0.013). Conclusion: There is a low frequency of the stromelysin-1 promoter 5A allele in the Chinese population in Taiwan. How stromelysin-1 5A/6A polymorphism affects ISR appears to be linked to angina status. These results merit further study to identify patients carrying genotypes which put them at increased risk of ISR, and which matrix metalloproteinase inhibitors or drug-eluting stents are more effective for those at risk.",
keywords = "Angioplasty, Genetics, Restenosis, Stet, Stromelysin-1",
author = "Chiou, {Kuan Rau} and Chung, {Sheng Liang} and Charng, {Min Ji}",
year = "2005",
month = "1",
day = "1",
doi = "10.1016/S1726-4901(09)70084-X",
language = "English",
volume = "68",
pages = "506--512",
journal = "Journal of the Chinese Medical Association",
issn = "1726-4901",
publisher = "Elsevier Taiwan LLC",
number = "11",

}

TY - JOUR

T1 - 5A/6A polymorphism of the stromelysin-1 gene and angiographic restenosis after coronary artery stenting

AU - Chiou, Kuan Rau

AU - Chung, Sheng Liang

AU - Charng, Min Ji

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Background: Coronary stent deployment is a major advance in interventional treatment, but 20-40% of patients still develop in-stent restenosis (ISR) due to neointimal hyperplasia. Genetic factors play a role in restenosis. This study investigated the frequency of 5A/6A polymorphism in the promoter of the stromelysin-1 gene, and the issue of whether it contributes to restenosis among patients receiving coronary stent in the Chinese population in Taiwan. Methods: We investigated 344 symptomatic patients after successful coronary stent placement. All patients received repeated angiography after 6 months, or earlier if clinically indicated. Angiographic restenosis was defined as ≥ 50% diameter stenosis at follow-up. Genotyping for stromelysin-1 promoter was based on a polymerase chain reaction technique. Results: The stromelysin-1 gene promoter genotypes 5A5A, 5A6A, and 6A6A were distributed in 3.5%, 22.7%, and 73.8% of patients, respectively. The frequency of the 6A allele was 0.85. There was no significant difference in angiographic ISR between the non-6A6A and 6A6A groups (28.9% and 37.0%, respectively, p = 0.165). However, subgroup analysis revealed a significant difference in patients according to angina status. Among the 5A5A and 5A6A genotype groups, patients with unstable angina had significantly higher ISR rates than those with stable angina (48% vs 21.5%, p = 0.013). On the other hand, among patients with stable angina, those with a 6A6A genotype had a higher ISR rate than those with a non-6A6A genotype (p = 0.029), making the 6A6A genotype an independent predictor of ISR (odds ratio, 2.57; 95% confidence interval, 1.22-5.41; p = 0.013). Conclusion: There is a low frequency of the stromelysin-1 promoter 5A allele in the Chinese population in Taiwan. How stromelysin-1 5A/6A polymorphism affects ISR appears to be linked to angina status. These results merit further study to identify patients carrying genotypes which put them at increased risk of ISR, and which matrix metalloproteinase inhibitors or drug-eluting stents are more effective for those at risk.

AB - Background: Coronary stent deployment is a major advance in interventional treatment, but 20-40% of patients still develop in-stent restenosis (ISR) due to neointimal hyperplasia. Genetic factors play a role in restenosis. This study investigated the frequency of 5A/6A polymorphism in the promoter of the stromelysin-1 gene, and the issue of whether it contributes to restenosis among patients receiving coronary stent in the Chinese population in Taiwan. Methods: We investigated 344 symptomatic patients after successful coronary stent placement. All patients received repeated angiography after 6 months, or earlier if clinically indicated. Angiographic restenosis was defined as ≥ 50% diameter stenosis at follow-up. Genotyping for stromelysin-1 promoter was based on a polymerase chain reaction technique. Results: The stromelysin-1 gene promoter genotypes 5A5A, 5A6A, and 6A6A were distributed in 3.5%, 22.7%, and 73.8% of patients, respectively. The frequency of the 6A allele was 0.85. There was no significant difference in angiographic ISR between the non-6A6A and 6A6A groups (28.9% and 37.0%, respectively, p = 0.165). However, subgroup analysis revealed a significant difference in patients according to angina status. Among the 5A5A and 5A6A genotype groups, patients with unstable angina had significantly higher ISR rates than those with stable angina (48% vs 21.5%, p = 0.013). On the other hand, among patients with stable angina, those with a 6A6A genotype had a higher ISR rate than those with a non-6A6A genotype (p = 0.029), making the 6A6A genotype an independent predictor of ISR (odds ratio, 2.57; 95% confidence interval, 1.22-5.41; p = 0.013). Conclusion: There is a low frequency of the stromelysin-1 promoter 5A allele in the Chinese population in Taiwan. How stromelysin-1 5A/6A polymorphism affects ISR appears to be linked to angina status. These results merit further study to identify patients carrying genotypes which put them at increased risk of ISR, and which matrix metalloproteinase inhibitors or drug-eluting stents are more effective for those at risk.

KW - Angioplasty

KW - Genetics

KW - Restenosis

KW - Stet

KW - Stromelysin-1

UR - http://www.scopus.com/inward/record.url?scp=28644443548&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28644443548&partnerID=8YFLogxK

U2 - 10.1016/S1726-4901(09)70084-X

DO - 10.1016/S1726-4901(09)70084-X

M3 - Article

VL - 68

SP - 506

EP - 512

JO - Journal of the Chinese Medical Association

JF - Journal of the Chinese Medical Association

SN - 1726-4901

IS - 11

ER -